Author, as appears in the article.: Moustafa F, Pesavento R, di Micco P, González-Martínez J, Quintavalla R, Peris ML, Porras JA, Falvo N, Baños P, Monreal M, RIETE Investigators

Department: Medicina i Cirurgia

URV's Author/s: Porras Ledantes, Jose Antonio

Keywords: Hashtag Etiqueta «#» @uroweb @residentesaeu @infoAeu

Abstract: We assessed the real-life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3,578 of 18,853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE recurrences (hazard ratio (HR): 3.10; 95% confidence interval (CI): 2.47-3.88), major bleeds (HR: 4.10; 95% CI: 3.38-4.96), and deaths (HR: 9.47; 95% CI: 8.46-10.6) than those without exclusion criteria. During initial therapy, no patient with exclusion criteria on DOACs (n = 115) recurred, but those on rivaroxaban bled less often (adjusted HR: 0.18; 95% CI: 0.04-0.79) than those on unfractionated heparin (n = 224) and similar to those (n = 3,172) on low-molecular-weight (LMWH) heparin. For long-term therapy, patients on rivaroxaban (n = 151) had nonsignificantly fewer VTE recurrences (adjusted HR: 0.74; 95% CI: 0.08-1.32) and major bleeds (adjusted HR: 0.41; 95% CI: 0.15-1.15) than those on LMWH (n = 2,071). The efficacy and safety of DOACs were similar to standard therapy.© 2017 American Society for Clinical Pharmacology and Therapeutics.

Thematic Areas: Saúde coletiva Química Pharmacology (medical) Pharmacology & pharmacy Pharmacology Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Ciências biológicas ii Ciências biológicas i Biotecnología

licence for use: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 00099236

Author's mail: joseantonio.porras@urv.cat

Author identifier: 0000-0001-6418-1822

Record's date: 2023-02-22

Papper version: info:eu-repo/semantics/acceptedVersion

Link to the original source: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.781

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Papper original source: Clinical Pharmacology & Therapeutics. (): 684-691

APA: Moustafa F, Pesavento R, di Micco P, González-Martínez J, Quintavalla R, Peris ML, Porras JA, Falvo N, Baños P, Monreal M, RIETE Investigators (2018). Real-life use of anticoagulants in venous thromboembolism with focus on patients with exclusion criteria for direct oral anticoagulants.. Clinical Pharmacology & Therapeutics, (), 684-691. DOI: 10.1002/cpt.781

Article's DOI: 10.1002/cpt.781

Entity: Universitat Rovira i Virgili

Journal publication year: 2018

Publication Type: Journal Publications